

Product information

Information about other products is available at: www.demeditec.com



Instruction for use

Rheumatoid Factor IgG ELISA

Enzyme Immunoassay for quantitative determination of IgG
Rheumatoid Factors in human serum or plasma



DE7640



96 Tests

PRINCIPLE OF THE TEST

Fc fragments of highly purified human Immunoglobulin G are coated on to microwells. Antibodies against the coated antigen, if present in diluted patient sample, bind to the respective antigen. Washing of the microwells removes unbound unspecific serum and plasma components. Horseradish peroxidase (HRP) conjugated anti-human antibodies immunologically detect the bound patient antibodies forming a conjugate/antibody/antigen complex. Washing of the microwells removes unbound conjugate. An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue colour. The addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow colour is measured photometrically at 450 nm. The amount of colour is directly proportional to the concentration of antibodies present in the original sample.

SUMMARY AND EXPLANATION OF THE TEST

The presence of IgM Rheumatoid Factor (RF) in the serum is the sole serological indicator included in the ACR list of criteria for the diagnosis of RA. RFs are a subset of antiglobulins directed against the Fc region of IgG. In this definition we do not include antibodies to the IgG Fab region and pepsin agglutinators, directed against neoantigens on IgG exposed by pepsin cleavage. It is claimed that the majority of antiglobulin activity in normal serum is Fab-specific, whereas an-tiglobulin from RA patients is mostly Fc-specific. RFs are present in the serum of 75-80% of patients with RA at some time during the disease course. However, RFs are also found in the serum of patients with infectious and autoimmune diseases, hyperglobulinemias, B-cell lymphoproliferative disorders and in the aged population. This suggests that RF may be a finding associated with B-cell hyperactivity.

Rheumatoid factors which have been found among the IgM, IgG and IgA classes of immunoglobulins, reacting only with xenogeneic Fc are not autoantibodies and are unlikely to be of pathological significance. However, RFs can bind IgG from many species, including autologous IgG, when immobilised on surfaces. Autologous binding is of higher affinity than xenogeneic binding. The here presented test systems for the determination of rheumatoid factors uses only human Fc-fragments as coated antigen.

It is generally considered that high titers of RF are associated with more severe disease and the presence of extra-articular features and rheumatoid nodules. This conclusion may depend on the disease duration. Serum IgM RF may precede the onset of RA by several years. A high titer of RF in non-RA individuals is associated with increased risk of developing RA. In the first 2 years of RA (early RA), serum levels of IgM, IgG and IgA RF do not correlate with disease activity. Serum IgG and IgA RF in these years are prognostic of erosive joint disease.

In established RA, high titer serum IgM RF correlates with the presence of articular disease and nodules but not with systemic disease activity. The presence of either IgG or IgA RF in patients with long-standing RA may be a good prognostic indicator of systemic manifestations. IgG and IgM RF are associated with extra-articular RA including rheumatoid vasculitis and nodules. The presence of IgM RF containing immune complexes with bound complement (C1q) is also associated with extra-articular RA.

CONTENTS OF THE KIT

Sufficient for 96 determinations

1 One divisible microplate consisting of 12 modules of 8 wells each. Ready to use.

5x 1.5 ml Calibrator A-E (0, 15, 50, 150, 500 U/ml), containing rheumatoid factor in a serum/buffer matrix (PBS, BSA, detergent, NaN₃ 0.09%), yellow. Ready to use.

2x 1.5 ml Control positive (1) and negative (2), containing rheumatoid factor in a serum/buffer matrix (PBS, BSA, detergent, NaN₃ 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.

20 ml Sample Buffer P, containing PBS, BSA, detergent, preservative NaN₃ 0.09%, yellow, 5x conc.

15 ml Enzyme Conjugate containing anti-human IgG antibodies, HRP labelled; PBS, BSA, detergent, preservative ProClin 300 0.05%, light red. Ready to use.

15 ml TMB Substrate; containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.

15 ml Stop Solution; contains acid. Ready to use.

20 ml Wash Solution, containing Tris, detergent, preservative NaN₃ 0.09%; 50 x conc.

1 Instruction for Use

1 Certificate of Analysis

MATERIALS REQUIRED

- Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 µl
- Vortex mixer
- Pipettes for 10 µl, 100 µl and 1000 µl
- Laboratory timing device
- Distilled or deionised water
- Measuring cylinder for 1000 ml and 100 ml
- Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

SPECIMEN COLLECTION, STORAGE AND HANDLING

- Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8 °C for up to five days or stored at -20 °C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- Testing of heat-inactivated sera is not recommended.

STORAGE AND STABILITY

- Store test kit at 2-8 °C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store microplate sealed and desiccated in the clip bag provided.
- Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash solution and Sample Buffer are stable for at least 30 days when stored at 2-8 °C. We recommend consumption on the same day.

PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28 °C) prior to use.
- Prepare all reagents and samples. Once started, perform the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- Perform the assay steps only in the order indicated.
- Always use fresh sample dilutions.
- Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- Wash microwells thoroughly and remove the last droplets of wash solution.
- All incubation steps must be accurately timed.
- Do not re-use microplate wells.

WARNINGS AND PRECAUTIONS

- All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- Stop solution contains acid, classification is non-hazardous. Avoid contact with skin.
- Control, calibrator, sample buffer and wash solution contain sodium azide (NaN₃) 0.09% as preservative. This concentration is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.
- During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:
- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin, wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running water for at least 10 minutes. Get medical attention if necessary.
- Personal precautions, protective equipment and emergency procedures:
- Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.
- Exposure controls / personal protection: Wear protective gloves of nitrile rubber or natural latex. Wear protective glasses. Used according to intended use no dangerous reactions known.
- Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
- For disposal of laboratory waste the national or regional legislation has to be observed.
- Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

PREPARATION OF REAGENTS

Wash Solution

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

Sample Buffer P

Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

Preparation of samples

Dilute patient samples 1:100 before the assay: Put 990 µl of prediluted sample buffer in a polystyrene tube and add 10 µl of sample. Mix well. Note: Calibrators / Controls are ready to use and need not be diluted.

TEST PROCEDURE

Prepare enough microplate modules for all calibrators / controls and patient samples.

1. Pipette **100 µl** of calibrators, controls and prediluted patient samples into the wells.
2. Incubate for **30 minutes** at room temperature (20-28 °C).
3. Discard the contents of the microwells and **wash 3 times with 300 µl** of wash solution.
4. Dispense **100 µl** of enzyme conjugate into each well.
5. Incubate for **15 minutes** at room temperature.
6. Discard the contents of the microwells and **wash 3 times with 300 µl** of wash solution.
7. Dispense **100 µl** of TMB substrate solution into each well.
8. Incubate for **15 minutes** at room temperature
9. Add **100 µl** of stop solution to each well of the modules
10. Incubate for **5 minutes** at room temperature.
11. Read the optical density at 450 nm (reference 600-690nm) and calculate the results. The developed colour is stable for at least 30 minutes. Read during this time.

Example for a pipetting scheme:

	1	2	3	4	5	6	7	8	9	10	11	12
A	A	P2										
B	B	P3										
C	C											
D	D											
E	E											
F	C+											
G	C-											
H	P1											

P1, ... patient sample A-E calibrators C+, C- controls

VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit. If these quality control criteria are not met the assay run is invalid and should be repeated.

CALCULATION OF RESULTS

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of patient samples may then be estimated from the calibration curve by interpolation. Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

PERFORMANCE CHARACTERISTICS**CALIBRATION**

This assay system is calibrated in relative arbitrary units. Calibration is related to 1st British Standard Preparation 64/2 for Rheumatoid Factor.

Measuring range

The calculation range of this ELISA assay is 0 - 500 U/ml

Expected values

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off 20 U/ml

Interpretation of results

Negative: < 20 U/ml

Positive: ≥ 20 U/ml

Linearity

Patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper/ lower end of linearity. Activity for each dilution was calculated from the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

Sample	Dilution	Observed U/ml	Expected U/ml	O/E [%]
1	1:100	652.3	560.3	116
.	1:200	293.9	280.2	105
.	1:400	142.7	140.1	102
.	1:800	64.4	70.0	92
.	1:1600	36.3	35.0	104
.	1:3200	15.7	17.5	90
2	1:100	490.2	452.7	108
.	1:200	214.5	226.4	95
.	1:400	108.9	113.2	96
.	1:800	53.3	56.6	94
.	1:1600	26.1	28.3	92
.	1:3200	14.2	14.1	101
3	1:100	269.0	260.5	103
.	1:200	123.4	130.3	95
.	1:400	58.9	65.1	90
.	1:800	27.4	32.6	84
.	1:1600	15.7	16.3	96
.	1:3200	7.1	8.1	88

Limit of detection

Functional sensitivity was determined to be: 1 U/ml

Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparin). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay		
Sample	Mean U/ml	CV %
1	22.8	5.5
2	65.3	7.4
3	160.7	6.9

Inter-Assay		
Sample	Mean U/ml	CV %
1	27.1	6.5
2	54.0	7.2
3	136.8	7.8

Study results

Study population	n	n Pos	%
Rheumatoid Arthritis	302	252	83.4
Normal human sera	169	16	9.5

Clinical Diagnosis

	Pos	Neg	
Pos	252	16	
Neg	50	153	
	302	169	471

Sensitivity: 83.4 %

Specificity: 90.5 %

Overall agreement: 86.0 %

LIMITATIONS OF THE PROCEDURE





This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually. The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establish its own ranges according to ISO 15189 or other applicable laboratory guidelines.

REFERENCES

1. Arinbjarnarson S., Jonsson T., Steinsson K. et al. IgA rheumatoid factor correlates with changes in B and T lymphocyte subsets and disease manifestations in rheumatoid arthritis. *J. Rheumatol.* 1997; 24: 269-274.
2. Borretzen M., Mellbye O. J., Thompson K. M., Natvig J. B. Rheumatoid Factors. In: Peter J. B., Shoenfeld Y. eds. *Autoantibodies*. 1 ed. Amsterdam: Elsevier, 1996: 706-715.
3. Brown P. B., Nardella F. A., Mannik M. Human complement activation by self-associated IgG rheumatoid factors. *Arthritis Rheum.* 1982; 25: 1101-1107.
4. Ernst E., Espersen G. T., Andersen M. V., Grunnet N. RF-classes (IgM, IgG, IgA) in a group of highly active RA-patients in relation to disease activity and treatment. *Scand. J. Rheumatol. Suppl.* 1988; 75: 250-255.
5. Espersen G. T., Ernst E., Vestergaard M., Grunnet N. ELISA estimations of rheumatoid factor IgM, IgA, and IgG in sera from RA patients with high disease activity. DTT treatment studies. *Scand. J. Rheumatol. Suppl.* 1988; 75: 40-45.
6. Houssien D. A., Jonsson T., Davies E., Scott D. L. Clinical significance of IgA rheumatoid factor subclasses in rheumatoid arthritis. *J. Rheumatol.* 1997; 24:2119-2122.

7. Jonsson T., Arinbjarnarson S., Thorsteinsson J. et al. Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis. *Scand. J. Rheumatol.* 1995;24: 372-375.
8. Kleveland G, Egeland T, Lea T. Quantitation of rheumatoid factors (RF) of IgM, IgA and IgG isotypes by a simple and sensitive ELISA. Discrimination between false and true IgG-RF. *Scand. J. Rheumatol. Suppl.* 1988; 75: 15-24.
9. Mogk M., Weise I., Welcker M., Oppermann M., Helmke K. Bedeutung der Rheumafaktor-Immunglobulinklassen IgG, IgA und IgM in der Diagnostik rheumatologischer und immunologischer Erkrankungen. *Clin. Lab.* 1995; 41: 885-891.
10. Paimela L., Palosuo T., Leirisalo-Repo M., Helve T., Aho K. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis. *Br. J. Rheumatol.* 1995; 34: 1146-1150.
11. Pope R. M. Rheumatoid arthritis: pathogenesis and early recognition. *Am. J. Med.* 1996; 100: 3S-9S.
12. Scutellari P. N., Orzincolo C. Rheumatoid arthritis: sequences. *Eur. J. Radiol.* 1998; 27 Suppl. 1: S31-S38
13. Swedler W., Wallman J., Froelich C. J., Teodorescu M. Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. *J. Rheumatol.* 1997; 24: 1037-1044.
14. Winska W. H., Thompson K., Young A., Corbett M., Shipley M., Hay F. IgA and IgM rheumatoid factors as markers of later erosive changes in rheumatoid arthritis (RA). *Scand. J. Rheumatol. Suppl.* 1988; 75: 238-243.

SYMBOLS USED WITH DEMEDITEC ASSAYS

Symbol	English	Deutsch	Français	Español	Italiano
	Consult instructions for use	Gebrauchsanweisung beachten	Consulter les instructions d'utilisation	Consulte las instrucciones de uso	Consultare le istruzioni per l'uso
	European Conformity	CE-Konformitätskennzeichnung	Conformité aux normes européennes	Conformidad europea	Conformità europea
	In vitro diagnostic device	In-vitro-Diagnostikum	Usage Diagnostic in vitro	Para uso Diagnóstico in vitro	Per uso Diagnostica in vitro
	For research use only	Nur für Forschungszwecke	Seulement dans le cadre de recherches	Sólo para uso en investigación	Solo a scopo di ricerca
	Catalogue number	Katalog-Nr.	Numéro de catalogue	Número de catálogo	Numero di Catalogo
	Lot. No. / Batch code	Chargen-Nr.	Numéro de lot	Número de lote	Numero di lotto
	Contains sufficient for <n> tests/	Ausreichend für "n" Ansätze	Contenu suffisant pour "n" tests	Contenido suficiente para <n> ensayos	Contenuto sufficiente per "n" saggi
	Storage Temperature	Lagerungstemperatur	Température de conservation	Temperatura de conservación	Temperatura di conservazione
	Expiration Date	Mindesthaltbarkeitsdatum	Date limite d'utilisation	Fecha de caducidad	Data di scadenza
	Legal Manufacturer	Hersteller	Fabricant	Fabricante	Fabbricante
Distributed by	Distributor	Vertreiber	Distributeur	Distribuidor	Distributore
Content	Content	Inhalt	Conditionnement	Contenido	Contenuto
Volume/No.	Volume / No.	Volumen/Anzahl	Volume/Quantité	Volumen/Número	Volume/Quantità